Principal Financial Group Inc. Sells 5,583 Shares of United Therapeutics Corporation $UTHR

Principal Financial Group Inc. lowered its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 105,767 shares of the biotechnology company’s stock after selling 5,583 shares during the quarter. Principal Financial Group Inc.’s holdings in United Therapeutics were worth $44,339,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Wilmington Savings Fund Society FSB raised its position in shares of United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares in the last quarter. WealthCollab LLC increased its stake in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. True Wealth Design LLC raised its position in United Therapeutics by 738.5% during the third quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 96 shares during the period. Finally, Root Financial Partners LLC bought a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $51,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Price Performance

Shares of UTHR opened at $482.59 on Thursday. The firm has a market capitalization of $20.78 billion, a price-to-earnings ratio of 18.29, a PEG ratio of 2.54 and a beta of 0.85. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $519.99. The company has a 50-day moving average of $486.95 and a 200 day moving average of $424.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 1,000 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the sale, the director directly owned 4,190 shares in the company, valued at approximately $2,136,900. This represents a 19.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $469.89, for a total value of $3,900,087.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at $17,283,024.09. The trade was a 18.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 537,914 shares of company stock worth $257,813,558. Company insiders own 10.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. HC Wainwright boosted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Royal Bank Of Canada lifted their price objective on shares of United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Wells Fargo & Company boosted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.